Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

References

• Zhang S, Kulkarni AA, Xu B, et al. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 2020;10(3):33. doi:10.1038/s41408-020-0298-1
   PubMed Web of Science ®Google Scholar
• Landgren O, Sonneveld P, Jakubowiak A, et al. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019;33(9):1. doi:10.1038/s41375-019-0517-6
   PubMed Web of Science ®Google Scholar
• Facon T, Anderson K. Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology. 2018;2018(1):83–87. doi:10.1182/asheducation-2018.1.83
   PubMedGoogle Scholar
• Engelhardt M, Yong K, Bringhen S, Wäsch R. Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the carthadex (KTd)-trial update? Haematologica. 2019;104(11):2128–2131. doi:10.3324/haematol.2019.228684
   PubMed Web of Science ®Google Scholar
• Ziogas DC, Terpos E, Kastritis E, Dimopoulos Ma. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017;18(17):1883–1897. doi:10.1080/14656566.2017.1404575
   PubMed Web of Science ®Google Scholar
• Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63–69. doi:10.1182/blood-2014-03-563759
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Magen H. A practical review on carfilzomib in multiple myeloma. Eur J Haematol. 2016;96(6):564–577. doi:10.1111/ejh.12749
   PubMed Web of Science ®Google Scholar
• Accardi F, Toscani D, Bolzoni M, Dalla Palma B, Aversa F, Giuliani N. Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling. Biomed Res Int. 2015;2015:172458. doi:10.1155/2015/172458
   PubMed Web of Science ®Google Scholar
• Shaji KK, Natalie SC, Kehinde A, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(12):1685–1717. doi:10.6004/jnccn.2020.0057
   PubMedGoogle Scholar
• Alsina M, Landgren CO, Raje N, et al. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM). Clin Lymphoma Myeloma Leuk. 2019;19(10):e52. doi:10.1016/j.clml.2019.09.079
   Web of Science ®Google Scholar
• Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, et al. Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma. Blood Cancer J. 2020;10(3). doi:10.1038/s41408-020-0297-2
   Web of Science ®Google Scholar
• Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801–1809. doi:10.1182/blood-2012-04-422683
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Raje N, Vij R, et al. High rate of sustained minimal residual disease negativity predicts prolonged survival for the overall patient population in the phase 2 KRd plus autologous stem cell transplantation MMRC trial. Blood. 2017;130(Supplement 1):4533.
   Google Scholar
• Kazandjian D, Korde N, Mailankody S, et al. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1781–1783. doi:10.1001/jamaoncol.2018.5457
   PubMed Web of Science ®Google Scholar
• Korde N, Mailankody S, Smith EL, et al. MRD response-driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone. Blood. 2018;132:1983.
   Google Scholar
• Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746–754. doi:10.1001/jamaoncol.2015.2010
   PubMed Web of Science ®Google Scholar
• Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous stem cell transplantation, krd consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma (NDMM) patients: primary results of the intergroupe francophone du myélome (IFM) krd phase II study. Blood. 2016;128(22):1142.
   Web of Science ®Google Scholar
• Zimmerman T, Raje NS, Vij R, et al. Final results of a phase 2 trial of extended treatment (TX) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM). Blood. 2016;128(22):675. doi:10.1182/blood.V128.22.675.675
   Web of Science ®Google Scholar
• Wester R, Van Der Holt B, Asselbergs E, et al. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the carthadex trial. Haematologica. 2019;104(11):2265–2273. doi:10.3324/haematol.2018.205476
   PubMed Web of Science ®Google Scholar
• Bringhen S, Cerrato C, Petrucci MT, et al. A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCD) for Newly Diagnosed Multiple Myeloma. Washington, DC: American Society of Hematology; 2013.
   Google Scholar
• Larocca A, Petrucci MT, Conticello C, et al. Updated results of a phase ii study with carfilzomib, cyclophosphamide and dexamethasone (CCD) for newly diagnosed transplant ineligible multiple myeloma patients. HemaSphere. 2018;2:234.
   Google Scholar
• Bensinger WI, Vescio R, Gasparetto C, et al. A multicenter phase 1b, open-label, dose-finding pilot study to evaluate the combination of carfilzomib and cyclophosphamide with dexamethasone (CCyD) prior to autologous stem cell transplant (ASCT) in patients with transplant eligible newly diagnosed multiple myeloma. Blood. 2014;124(21):4739–4739.
   Web of Science ®Google Scholar
• Boccia RV, Bessudo A, Agajanian R, et al. A multicenter, open-label, Phase 1b Study of carfilzomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple myeloma patients (CHAMPION-2). Clin Lymphoma Myeloma Leuk. 2017;17(7):433–437. doi:10.1016/j.clml.2017.05.009
   PubMed Web of Science ®Google Scholar
• Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979–985. doi:10.1038/leu.2017.327
   PubMed Web of Science ®Google Scholar
• Chen Y, Gopalakrishnan S, Ooi M, et al. Carfilzomib, cyclophosphamide, and dexamethasone in transplant eligible newly diagnosed multiple myeloma: preliminary result of sghmm1 trial, high-risk cohort (NCT02217163). HemaSphere. 2018;2:589.
   Google Scholar
• Yong K, Popat R, Wilson W, et al. Efficacy and safety of carfilzomib at 56 mg/m2 with cyclophosphamide and dexamethasone (K56Cd) in newly diagnosed multiple myeloma patients followed by ASCT or K56Cd consolidation: initial results of the Phase 2 Cardamon Study. Blood. 2019;134(Supplement_1):861. doi:10.1182/blood-2019-127992
   Google Scholar
• Leleu X, Fouquet G, Richez V, et al. Carfilzomib weekly plus melphalan and prednisone in newly diagnosed transplant-ineligible multiple myeloma (IFM 2012-03): a phase I trial. Clin Cancer Res. 2019;25(14):4224–4230. doi:10.1158/1078-0432.CCR-18-3642
   PubMed Web of Science ®Google Scholar
• Moreau P, Kolb B, Attal M, et al. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. Blood. 2015;125(20):3100–3104. doi:10.1182/blood-2015-02-626168
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Reeder CB, Libby EN, et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol. 2015;169(2):219–227. doi:10.1111/bjh.13296
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Davies F, Cairns D, et al. Quadruplet KCRD (carfilzomib, cyclophosphamide, lenalidomide and dexamethasone) induction for newly diagnosed myeloma patients. Clin Lymphoma Myeloma Leuk. 2019;19(10):e2. doi:10.1016/j.clml.2019.09.003
   Web of Science ®Google Scholar
• Chari A, Usmani SZ, Krishnan A, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRD) in patients with newly diagnosed multiple myeloma (mmy1001): updated results from an open-label, phase 1b study. Blood. 2017;130:3110.
   Google Scholar
• Landgren O, Hultcrantz M, Lesokhin AM, et al. Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study. Blood. 2019;134(Supplement_1):862. doi:10.1182/blood-2019-126378
   Web of Science ®Google Scholar
• Weisel K, Asemissen AM, Schieferdecker A, et al. Isatuximab, carfilzomib, lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk multiple myeloma: results of the safety run-in cohort in the phase II, multicenter GMMG-CONCEPT trial. Clin Lymphoma Myeloma Leuk. 2019;19(10):e17. doi:10.1016/j.clml.2019.09.024
   Web of Science ®Google Scholar
• Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, carfilzomib, lenalidomide and dexamethasone (dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-KRd consolidation in patients with newly diagnosed multiple myeloma (NDMM). Blood. 2019;134:860.
   PubMed Web of Science ®Google Scholar
• Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019;133(18):1953–1963. doi:10.1182/blood-2018-09-874396
   PubMed Web of Science ®Google Scholar
• Kumar S, Jacobus SJ, Cohen AD, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol. 2020;38(18_suppl):LBA3–LBA. doi:10.1200/JCO.2020.38.18_suppl.LBA3
   Web of Science ®Google Scholar
• Forsberg PA, Rossi AC, Boyer A, et al. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019;94(5):539–545. doi:10.1002/ajh.25435
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mina R, Petrucci MT, et al. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica. 2019;104(8):1640–1647. doi:10.3324/haematol.2018.208272
   PubMed Web of Science ®Google Scholar
• Team AT. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381(9875):1391–1403. doi:10.1016/S0140-6736(12)62198-9
   PubMed Web of Science ®Google Scholar
• Moreau P, Stewart KA, Dimopoulos M, et al. Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: a post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials. Cancer Med. 2020;9(9):2989–2996. doi:10.1002/cam4.2945
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi:10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• O’dwyer M, Henderson R, Naicker S, et al. CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study. Blood Adv. 2019;3(12):1815–1825. doi:10.1182/bloodadvances.2019000010
   PubMed Web of Science ®Google Scholar
• Bringhen S, Mina R, Petrucci M, et al. Incidence and risk factors of cardiovascular adverse events in a large population of newly-diagnosed, transplant ineligible myeloma patients treated with carfilzomib. In: Haematologica. Via Giuseppe Belli 4, 27100 Pavia, Italy: Ferrata Storti Foundation; 2017;102:510–511.
   Google Scholar
• Bringhen S, Milan A, Ferri C, et al. Cardiovascular adverse events in modern myeloma therapy–incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica. 2018;103(9):1422–1432. doi:10.3324/haematol.2018.191288
   PubMed Web of Science ®Google Scholar
• Ball S, Behera TR, Anwer F, Chakraborty R. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol. 2020;99(6):1265–1271. doi:10.1007/s00277-020-04062-x
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   Google Scholar